Favourable prognostic factors of subsequent screen-detected breast cancers among women aged 50-69

European Journal of Cancer Prevention

Volumn 21, Issue 6, 2012, Pages 499-506

  Chiarelli, Anna M ^a   Edwards, Sarah A ^a   Sheppard, Amanda J ^b   Mirea, Lucia ^c   Chong, Nelson ^a   Paszat, Lawrence ^a   Shumak, Rene S ^a   O'Malley, Frances P ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Breast cancer; Breast screening; Interval cancers; Mammography; Symptomatic cancers

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGED; BREAST CANCER; CANCER GRADING; CANCER PROGNOSIS; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MITOSIS INDEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TIME FACTORS;

EID: 84866952828     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328350b0f4     Document Type: Review

References (38)

1. American Joint Committee on Cancer (2002). Cancer staging manual. 6th ed. New York, NY: Springer-Verlag.
2. Brekelmans CT, Peeters PH, Deurenberg JJ, Collette HJ (1995). Survival in interval breast cancer in the DOM screening programme. Eur J Cancer 31A:1830-1835.
3. Brekelmans CT, van Gorp JM, Peeters PH, Collette HJ (1996). Histopathology and growth rate of interval breast carcinoma. Characterization of different subgroups. Cancer 78:1220-1228.
4. Burke JP, Power C, Gorey TF, Flanagan F, Kerin MJ, Kell MR (2008). A comparative study of risk factors and prognostic features between symptomatic and screen detected breast cancer. Eur J Surg Oncol 34:149-153.
5. Burrell HC, Sibbering DM, Wilson AR, Pinder SE, Evans AJ, Yeoman LJ, et al. (1996). Screening interval breast cancers: mammographic features and prognosis factors. Radiology 199:811-817.
6. Chiarelli AM, Halapy E, Nadalin V, Shumak R, O'Malley F, Mai V (2006). Performance measures from 10 years of breast screening in the Ontario Breast Screening Program, 1990/91 to 2000. Eur J Cancer Prev 15:34-42.
7. Clayforth C, Fritschi L, McEvoy S, Byrne MJ, Wylie E, Threlfall T, et al. (2005). Assessing the effectiveness of a mammography screening service. ANZ J Surg 75:631-636.
8. Cowan WK, Angus B, Gray JC, Lunt LG, al-Tamimi SR (2000). A study of interval breast cancer within the NHS breast screening programme. J Clin Pathol 53:140-146.
9. Crosier M, Scott D, Wilson RG, Griffiths CD, May FE, Westley BR (1999). Differences in Ki67 and c-erbB2 expression between screen-detected and true interval breast cancers. Clin Cancer Res 5:2682-2688.
10. Dillon MF, Hill AD, Quinn CM, O'Doherty A, Crown J, Fleming FJ, et al. (2004). Surgical intervention in screen-detected patients versus symptomatic patients with breast cancer. J Med Screen 11:130-134.
11. Domingo L, Sala M, Servitja S, Corominas JM, Ferrer F, Martinez J, et al. (2010). Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes Control 21:1155-1164.
12. Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, et al. (2002). The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 95:458-469.
13. Elston CW, Ellis IO (1991). Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410.
14. Frisell J, Eklund G, Hellstrom L, Somell A (1987). Analysis of interval breast carcinomas in a randomized screening trial in Stockholm. Breast Cancer Res Treat 9:219-225.
15. Garvican L, Littlejohns P (1998). Comparison of prognostic and socio-economic factors in screen-detected and symptomatic cases of breast cancer. Public Health 112:15-20.
16. Gilliland FD, Joste N, Stauber PM, Hunt WC, Rosenberg R, Redlich G, Key CR (2000). Biologic characteristics of interval and screen-detected breast cancers. J Natl Cancer Inst 92:743-749.
17. Groenendijk RP, Bult P, Tewarie L, Peer PG, van der Sluis RF, Ruers TJ,Wobbes T (2000). Screen-detected breast cancers have a lower mitotic activity index. Br J Cancer 82:381-384.
18. Groenendijk RP, Bult P, Noppen CM, Boetes C, Ruers TJ, Wobbes T (2003). Mitotic activity index in interval breast cancers. Eur J Surg Oncol 29:29-31.
19. Hakama M, Holli K, Isola J, Kallioniemi OP, Karkkainen A, Visakorpi T, et al. (1995). Aggressiveness of screen-detected breast cancers. Lancet 345:221-224.
20. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. (2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48-e72.
21. Holmberg LH, Tabar L, Adami HO, Bergstrom R (1986). Survival in breast cancer diagnosed between mammographic screening examinations. Lancet 2:27-30.
22. Holowaty EJ, Marrett LD, Fehringer G (1995). Methods cancer incidence in Ontario: trends and regional variations in the 1980s. Toronto, Ontario: Publications Ontario.
23. Jaro MA (1995). Probabilistic linkage of large public health data files. Stat Med 14:491-498.
24. Kirsh VA, Chiarelli AM, Edwards SA, O'Malley FP, Shumak RS, Yaffe MJ, Boyd NF (2011). Tumor characteristics associated with mammographic detection of breast cancer in the Ontario breast screening program. J Natl Cancer Inst 103:942-950.
25. Klemi PJ, Toikkanen S, Rasanen O, Parvinen I, Joensuu H (1997). Mammography screening interval and the frequency of interval cancers in a population-based screening. Br J Cancer 75:762-766.
26. Marrett LD, Swift M, Reynolds DL, Clarke EA (1995). Geographic distribution of cancer in Ontario, Volume 1, Atlas of cancer mortality. Toronto, ON: Ontario Cancer Treatment and Research Foundation; pp. 1976-1985.
27. Miller AB (1996). Fundamental issues in screening for cancer. In: Schottenfeld D, Fraumeni JF Jr, editors. Cancer epidemiology and prevention. New York, NY: Oxford University Press; pp. 1433-1452.
28. Nagtegaal ID, Allgood PC, Duffy SW, Kearins O, Sullivan EO, Tappenden N, et al. (2011). Prognosis and pathology of screen-detected carcinomas: how different are they? Cancer 117:1360-1368.
29. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L (2009). Screening for breast cancer: an update for the US Preventive Services Task Force. Ann Intern Med 151:727-737, W237-742.
30. Paci E, Ponti A, Zappa M, Patriarca S, Falini P, Delmastro G, et al. (2005). Early diagnosis, not differential treatment, explains better survival in service screening. Eur J Cancer 41:2728-2734.
31. Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N,Watney EA, et al. (1999). Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 91:2020-2028.
32. SAS Institute Inc. (2004). Statistical Analysis Software 912. Cary, NC: SAS Institute.
33. Schroen AA, Wobbes T, van der Sluis RF (1996). Interval carcinomas of the breast: a group with intermediate outcome. J Surg Oncol 63:141-144.
34. Statistics Canada (1997). 1996 Census Dictionary Report No: 92-325-UIE. Ottawa, ON: Statistics Canada.
35. Tabár L, Vitak B, TonyChen HH, Yen MF, Duffy SW, Smith RA (2001). Beyond randomized controlled trials. Cancer 91:1724-1731.
36. Vitak B, Stal O, Manson JC, Thomas BA, Arnesson LG, Ekelund L, et al. (1997). Interval cancers and cancers in non-attenders in the Ostergotland mammographic screening programme. Duration between screening and diagnosis, S-phase fraction and distant recurrence. Eur J Cancer 33:1453-1460.
37. Wilkins R (1998). Geocodes/PCCF version 3 user's guide. Automated geographic coding based on the Statistics Canada postal code conversion files. Ottawa, ON: Health Statistics Division, Statistics Canada.
38. World Health Organization (1990). International classification of diseases for oncology (ICD-O). 2nd ed. Geneva: WHO.